PK k5T P Emgality_(galcanezumab)_LillyPlus_Formulaire_d_Inscription_2022/eform.propertiesSRv+TJS02T04222Tp Q0202J/KI,Iqu u!y9%@:91/471I3'3'2 8 4'1(5>%38($3?/a|FIn[fN*5L PK PK k5T Emgality_(galcanezumab)_LillyPlus_Formulaire_d_Inscription_2022/Emgality_(galcanezumab)_LillyPlus_Formulaire_d_Inscription_2022.html]{sHS5ߡͬKBĉ27l͝jAKFd[VTņקOsx]|`h½(?n|XΉl~6PbgȞ0"P"{l=7^>y_E4 nH١;jmM;oq2@/A1H Qq\